Date filters select awards with transaction activity in the period. Amounts below are lifetime award obligations. IDV values remain separate.
NATIONAL CORD BLOOD INVENTORYDepartment of Health and Human Services$67.0M obligationsEnds Sep 3, 2036
BORDETELLA-FREE BABOONS FOR PERTUSSIS INFECTION AND VACCINATION STUDIESDepartment of Health and Human Services$368.6K obligationsEnds Aug 31, 2027
OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC)Department of Health and Human Services$1.6M obligationsEnds Aug 31, 2027
PROJECT TITLE: LOW-DOSE ERLOTINIB AND MESALAMINE FOR PREVENTION OF COLITIS-ASSOCIATED COLORECTAL CANCER (CAC)Department of Health and Human Services$1.3M obligationsEnds Mar 24, 2028
BAA FY26C1FP7 MD ANDERSON ONCOLOGY CENTER FOR EXCELLENCE (OCE), EVALUATING BAYESIAN EFFECTIVE SAMPLE SIZE AND DECISION CRITERIA FOR PEDIATRIC AND RARE DISEASE TRIALSDepartment of Health and Human Services$752.3K obligationsEnds Sep 29, 2028
BORDETELLA-FREE BABOON STUDYDepartment of Health and Human Services$206.2K obligationsEnds Aug 9, 2027
OPERATION AND MAINTENANCE OF THE CHIMPANZEE CARE CENTER (CCC)Department of Health and Human Services$8.7M obligationsEnds Aug 31, 2026
MED PHYSICS PEER REVIEW SERVICESDepartment of Veterans Affairs$1.1M obligationsEnds Sep 29, 2027
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH DURATION OF PERTUSSIS IMMUNITY IN BABOONS STUDYDepartment of Health and Human Services$150.1K obligationsEnds Feb 28, 2025
FURTHER DEVELOPMENT OF IPSC-BASED VACCINE FOR COLON CANCER PREVENTIONDepartment of Health and Human Services$1.3M obligationsEnds Dec 25, 2026
RATIFICATION FOR CALIBRATION SERVICESDepartment of Veterans Affairs$2.8K obligationsEnds May 15, 2026
PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS-- TARGETING THE PARP PATHWAY FOR THE PREVENTION OF BREAST CANCERDepartment of Health and Human Services$1.1M obligationsEnds May 31, 2027
TARGETING STAT3 TO PREVENT NON-SMALL CELL LUNG CANCER (NSCLC) IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)Department of Health and Human Services$1.1M obligationsEnds Jun 14, 2026
TARGETING DKK1 WITH A DNA VACCINE TO PREVENT DEVELOPMENT OF MULTIPLE MYELOMADepartment of Health and Human Services$1.2M obligationsEnds Oct 25, 2026
MERKELOMV-AP STUDY (BABOONS)Department of Health and Human Services$202.1K obligationsEnds Sep 2, 2022
TIME-RESTRICTED FEEDING FOR PANCREATIC CANCER PREVENTIONDepartment of Health and Human Services$551.7K obligationsEnds Dec 19, 2026
DURATION OF PERTUSSIS IMMUNITY IN BABOONS STUDYDepartment of Health and Human Services$202.6K obligationsEnds Mar 31, 2023
TARGETING STAT3 TO PREVENT COLORECTAL CANCER SECONDARY TO INFLAMMATORY BOWEL DISEASEDepartment of Health and Human Services$930.2K obligationsEnds Mar 15, 2025
BAA-MD ANDERSON-STATISTICAL DESIGNS AND CONSIDERATIONS FOR DOSE OPTIMIZATION FY25C1FP6Department of Health and Human Services$1.2M obligationsEnds Sep 29, 2028
V105: NON-HUMAN PRIMATE ACQUISITIONDepartment of Health and Human Services$123.0K obligationsEnds Sep 18, 2026
TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCERDepartment of Health and Human Services$1.3M obligationsEnds Mar 14, 2027
MEDICAL PHYSICS PEER REVIEW OF RADIATION THERAPY QUALITY ASSURANCE OPERATIONSDepartment of Veterans Affairs$972.2K obligationsEnds Mar 12, 2025
BASE:PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY&INTERMEDIATE BIOMARKERS TASK ORDER: TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED…Department of Health and Human Services$840.8K obligationsEnds May 31, 2025
TASK ORDER TITLE: EVALUATION OF REAL-TIME METABOLIC IMAGING BIOMARKERS FOR DETECTION OF PANCREATIC PREMALIGNANT LESIONSDepartment of Health and Human Services$1.2M obligationsEnds Mar 15, 2025
IMMUNOGENICITY STUDY IN BABOONS FOLLOWING VACCINATION WITH EXPERIMENTAL ACELLULAR PERTUSSIS VACCINES.Department of Health and Human Services$425.6K obligationsEnds Mar 27, 2024